887927-14-2

Upstream product

• 500208-43-5 6-[4-benzyloxy-2-(tert-butyldiphenylsilanyloxy)-butyl]-tetrahydropyran-2-one 
• 1730-25-2 allylmagnesium bromide 

Downstream Products

• 887927-17-5 (S)-3-(tert-Butyl-diphenyl-silanyloxy)-4-[(2S,6R)-6-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethyl)-tetrahydro-pyran-2-yl]-butan-1-ol 
• 887927-18-6 (R)-3-(tert-Butyl-diphenyl-silanyloxy)-4-[(2S,6R)-6-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethyl)-tetrahydro-pyran-2-yl]-butyric acid 
• 887927-16-4 {(S)-3-Benzyloxy-1-[(2S,6R)-6-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethyl)-tetrahydro-pyran-2-ylmethyl]-propoxy}-tert-butyl-diphenyl-silane 
• 887927-20-0 C₆₂H₉₆O₁₄Si₂ 
• 1451061-85-0 (2S)-1-[(2R,6S)-6-(2-{[tert-butyl(diphenyl)silyl]oxy}-4-hydroxybutyl)tetrahydro-2H-pyran-2-yl]pent-4-en-2-ol 

Relevant academic research and scientific papers

Lead diversification through a prins-driven macrocyclization strategy: Application to C13-diversified bryostatin analogues

The design, synthesis, and biological evaluation of a novel class of C13-diversified bryostatin analogues are described. An innovative and general strategy based on a Prins macrocyclization-nucleophilic trapping cascade was used to achieve late-stage dive

Design, synthesis, and biological evaluation of a potent, PKC selective, B-ring analog of bryostatin

The first member of a new class of five-membered B-ring analogs of bryostatin has been synthesized and tested for its ability to bind and translocate protein kinase C (PKC). This synthesis extends the utility of our previously introduced macrotransacetali